Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREAM-AD: Amlitelimab in Moderate-to-Severe Atopic Dermatitis
NCT05131477Phase 2Completed
- Sponsor
- Kymab
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (5 arms), sponsored by Kymab. Primary endpoint: Percentage Change in Eczema Area and Severity Index From Baseline at 16 weeks. Started Dec 2021; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05131477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131477.